Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224281 | 0.85 | SLC6A2 (0.50) | TAAR1SLC6A2LOXL2SMN1; SMN2HIF1A | |
| SCHEMBL24371177 | 0.79 | LOXL2 (0.52) | TAAR1LOXL2KIF11MAOAMAOB | |
| SCHEMBL29342 | 0.78 | TAAR1 (0.56) | TAAR1SLC6A2LOXL2SMN1; SMN2HIF1A | |
| SCHEMBL10633769 | 0.78 | SLC6A2 (0.44) | TAAR1SLC6A2LOXL2SMN1; SMN2HIF1A | |
| SCHEMBL3438750 | 0.78 | SLC6A2 (0.50) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL29570480 | 0.77 | LOXL2 (0.50) | TAAR1LOXL2KIF11LMNAMAOB | |
| SCHEMBL21243974 | 0.77 | CYP1A2 (0.48) | TAAR1SLC6A2LOXL2SMN1; SMN2HIF1A | |
| Hydrochloric Acid SCHEMBL11047140 | 0.76 | TAAR1 (0.54) | TAAR1SLC6A2LOXL2SMN1; SMN2HIF1A | |
| SCHEMBL17288517 | 0.76 | SLC6A2 (0.43) | TAAR1SLC6A2LOXL2SMN1; SMN2HIF1A | |
| SCHEMBL10159611 | 0.76 | TSHR (0.46) | TAAR1SLC6A2LOXL2SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499494-B2 | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| CN-103201251-B | By the method for benzylamine compound initial preparation 2,2-difluoroethylamine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-02 | — | — | CN | disclosed |
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2015-07-23 | — | — | US | disclosed |
| EP-2638002-A1 | METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-8450528-B2 | Process for the preparation of 2,2-difluoroethylamine starting from a benzylamine compound | BAYER CROPSCIENCE AG (DE) | 2013-05-28 | — | — | US | disclosed |
| WO-2012062702-A1 | METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | BAYER CROPSCIENCE AG (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120123163-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | BAYER CROPSCIENCE AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | TAAR1 3038/4885SLC6A2 936/4885LOXL2 1413/4885 |
| US-20120123163-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE STARTING FROM A BENZYLAMINE COMPOUND | HDHD5, CTRB2, H1-2 | TAAR1 340/4885SLC6A2 676/4885LOXL2 3288/4885 |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | TAAR1 3038/4885SLC6A2 936/4885LOXL2 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.